To address this gap in knowledge, we used samples from 2 independent mechanistic clinical studies in patients with established type 1 diabetes (T1D) to compare the effect of anti–IL-6 (siltuximab) and anti–IL-6R (tocilizumab) therapies on T cell fate and function. This evidence concerns the gene IL6R and type 1 diabetes mellitus.